专利检索 ap:("Octapharma AG") AND inv:"ROEMISCH, Juergen" 第 1 页

1.

发明公开
TEST FOR HEMOLYTIC POTENTIAL OF PHARMACEUTICAL PRODUCTS AND FORMULATIONS FOR RISK MINIMIZATION 审中-公开
标题翻译： TEST为减少风险潜在溶血性医药产品和制剂

公开(公告)号：EP2900262A1

公开(公告)日：2015-08-05

申请号：EP13770475.5

申请日：2013-09-26

申请人： Octapharma AG

发明人： HEGER, Andrea , SVAE, Tor-Einar , ROEMISCH, Juergen , ZOECHLING, Alfred

IPC分类号： A61K39/395 , A61K47/00 , A61K9/00 , G01N33/49

CPC分类号： A61K47/183 , A61K39/39591 , C07K16/00 , C07K16/18 , G01N33/49 , G01N33/80

摘要： A non-hemolytic acidic composition comprising an immunoglobulin selected from immunoglobulin A, immunoglobulin G or immunoglobulin M at a pH value in the range of 4.65 to 5.7 comprising one or more excipients selected from amino acids, sugars and sugar alcohols in a concentration range of 100-350 mmol/l, in particular 200-350 mmol/l, characterized in that it displays an optical density (OD) in the range of 0.14 to -0.1 when the OD is determined in a spectrophotometer at 414 nm at a film thickness of 0.825 mm; and its use in an assay for determination of the hemolytic potential of intravenously applied pharmaceuticals and compositions and preparations displaying a reduced potential of hemolysis when being applied intravenously.

2.

发明公开
METHOD FOR PURIFICATION OF COMPLEMENT FACTOR H 审中-公开
标题翻译：程序对清洁补体因子H

公开(公告)号：EP2627348A1

公开(公告)日：2013-08-21

申请号：EP11770100.3

申请日：2011-10-13

申请人： Octapharma AG

发明人： BRANDSTAETTER, Hubert , SCHULZ, Petra , ROEMISCH, Juergen

IPC分类号： A61K38/17 , C07K1/18 , C07K14/435

CPC分类号： C07K14/472 , A61K38/1709 , C07K1/36 , C07K14/435 , C07K14/47

摘要： A method for purification of complement Factor H from a complement Factor H containing source such as blood or blood plasma, in particular a caprylate precipitate of a Factor H containing source, which is e.g. obtained by addition of caprylate ions to fractions of blood or plasma, comprising the steps of: a)providing a Factor H containing source, in particular reconstitution of caprylate precipitate to provide a complement Factor H containing solution; b)performing a cation exchange chromatography in particular as first chromatographic step; c)performing an anion exchange chromatography; d)performing a hydroxyl apatite chromatography; e)followed by ultra/diafiltration to obtain a complement Factor H concentrate.